SlideShare a Scribd company logo
DECLARATION OF HELSINKI (UNIT V)
SUBMITTED BY: PRACHI PANDEY, RAHUL PAL
M. PHARM (PHARMACEUTICS), IIIRD SEM, RESEARCH METHEDOLOGY AND BIOSTATISTICS
DEPARTMENT OF PHARMACEUTICS, NIMS INSTITUTE OF PHARMACY, NIMS UNIVERSITY, JAIPUR, RAJASTHAN,
303121, INDIA.
DECLARATION OF HELSINKI
 It is a set of ethical principles basically for clinical trails followed by medical researchers and given by
World Medical Association.
 As physician’s (investigator) duty in research is to protect the life, health, privacy and dignity of human
participant oversight by Institutional Review Board (IRB); Research Ethical Committee (REC) or Ethical
Review Board (ERB).
 Declaration of Helsinki was followed by Nuremberg code (because of nazii experiments) and
Thalidomide disaster {which was a pharmacovigilance failure; where pregnant women’s morning
sickness was tried to overcome by drug that lead to delivery of babies without limbs (phocomelia)}.
 9 Amendments in 1975, 1983, 1989, 1996, 2000, 2002, 2004, 2008, 2013.
 Regarded as cornerstone documents for human ethics.
HISTORY
 Adopted in June 1964.
 Amendments- 1975, 1983, 1989, 1996,2000,2002,2004,2008,2013
 First significant effort by medical community to regulate research.
 Prior to 1947 Nuremberg code only specific countries has National policies. (Germany Russia)
 Forms basis of most subsequent documents
 1947 declaration of the Nuremberg Code1948 declaration of Geneva
 Declaration of Geneva (1948) - the WMA binds the physician with the words. "The health of my patient
will be my first consideration".
GENERAL STATEMENT
 Purpose- directed towards the increase of knowledge about the
human condition in relation to its social and natural environment.
 Research is for the betterment of all.
 Conducted- dignity and well being. professional fair treatment and
transparency no greater risk.
 Evaluation- all stages of proposal (research design,
experimentation, deceleration of results, use of results) benefits and
dangers.
GOAL NEW KNOWLEDDE
PRINCIPLE
 First Principle – Objective of study is to outweigh risk. If risk is more either modify or stop the study
along with every thing must be monitored, assessed, documented with minimum risk.
 Second Principle – If vulnerable groups (pregnancy, sensitive, children, elderly, psychological issues) are
involved then increase chance additional harm protection must be provided along with consent even with
minors
 Third Principle - Before human study, scientific literature, lab and animal experiments is must to be read;
statements like regarding funding, sponsors, institutional afflation's, potential conflict of interest must be
submitted; research involving humans must confirm to generally accepted scientific principles and
through knowledge of scientific literature and methods; literature review and animal experiments must be
prior to human research.
PRINCIPLE
 Four Principle (Research Ethical Committee) – Before study, design to conduct the experiment must be
given to the National and International Ethical norms. Research submission about the final report with
study finding and conclusion in end of the study; research protocol must be reviewed by an independent
committee and conduct by medically/ scientifically qualified individuals; main aim is the participant
health, introduction to ethical committee, responsibility to check again and again, increase revolutionary
decision. If not done they have a reason to stop/ declare invalid.
 Five Principle (Privacy and Confidentiality) – Human subject and information must be private. Dignity,
privacy, confidentiality, participant’s physical/ mental integrity and life of participants should be
protected.
PRINCIPLE
 Six Principle (Informed Consent) – It is a written consent about the experiment that has to be conducted
by the volunteer independently after knowing about research and It must have aim, method, conflict of
interest, function, general outcome of study, voluntary , legally authorative represerntative.
 Seven Principle (Results) – Investigators are obliged to preserve the accuracy of results, negative and
positive results should be publically available.
 Eight Principle (Use of Placebo) – Intervention should be given (+) impact. CARE- avoid abuse of this
option.
 Nine Priciple (Post trail Provision) – Explain human subjects and provide help.
 Ten Principle (Unproven intervention in clinical practice) – Evaluate the efficacy and safety; new
information will be recorded and publically available.
ADDITIONAL PRINCIPLE
 The physician may combine medical research with medical care, only to the extent that the research is
justified by its potential prophylactic, diagnostic or therapeutic value.
 When medical research is combined with medical care, additional standards apply to protect the patients
who are research subjects.
 The benefits, risks, burdens and effectiveness of a new method should be tested against those of the best
current prophylactic, diagnostic, and therapeutic methods. This does not exclude the use of placebo, or no
treatment, in studies where no proven prophylactic, diagnostic or theraptic method exists.
 At the conclusion of the study, every patient entered into the study should be assured of access to the best
proven prophylactic, diagnostic and therapeutic methods identified by the study.
ADDITIONAL PRINCIPLE
 The physician should fully inform the patient which aspects of the care are related to the research. The
refusal of a patient to participate in a study must never interfere with the patient-physician relationship.
 In the treatment of a patient, where proven prophylactic, diagnostic and therapeutic methods do not exist
or have been ineffective, the physician, with informed consent from the patient, must be free to use
unproven or new prophylactic, diagnostic and therapeutic measures, if in the physician's judgment it
offers hope of saving life, reestablishing health or alleviating suffering. Where possible, these measures
should be made the object of research, designed to evaluate their safety and efficacy. In all cases, new
information should be recorded and, where appropriate, published. The other relevant guidelines of this
Declaration should be followed.
Research Methodology_UNIT_V_Declaration of Helsinki M. Pharm (IIIrd Sem.)

More Related Content

What's hot

General research methodology mpharm
General research methodology  mpharmGeneral research methodology  mpharm
General research methodology mpharm
AlkaDiwakar
 
Vendor relationship...fatality.
Vendor relationship...fatality.Vendor relationship...fatality.
Vendor relationship...fatality.
Sukh Pal Kashyap
 
Research Methodology General.ppt
Research  Methodology  General.pptResearch  Methodology  General.ppt
Research Methodology General.pptShama
 
M. Pharm: Research Methodology and biostatics
M. Pharm: Research Methodology and biostatics M. Pharm: Research Methodology and biostatics
M. Pharm: Research Methodology and biostatics
SONALI PAWAR
 
Cross over design, Placebo and blinding techniques
Cross over design, Placebo and blinding techniques Cross over design, Placebo and blinding techniques
Cross over design, Placebo and blinding techniques
Dinesh Gangoda
 
Research Methodology (M. Pharm, IIIrd Sem.)_UNIT_IV_CPCSEA Guidelines for Lab...
Research Methodology (M. Pharm, IIIrd Sem.)_UNIT_IV_CPCSEA Guidelines for Lab...Research Methodology (M. Pharm, IIIrd Sem.)_UNIT_IV_CPCSEA Guidelines for Lab...
Research Methodology (M. Pharm, IIIrd Sem.)_UNIT_IV_CPCSEA Guidelines for Lab...
RAHUL PAL
 
Declaration of Helsinki
Declaration of HelsinkiDeclaration of Helsinki
Declaration of Helsinki
ClinosolIndia
 
Declaration of helsinki powerpoint presentation
Declaration of helsinki powerpoint presentationDeclaration of helsinki powerpoint presentation
Declaration of helsinki powerpoint presentation
PoojaGupta767
 
Choice of control group in clinical trials
Choice of control group in clinical trialsChoice of control group in clinical trials
Choice of control group in clinical trials
Nagendra SR
 
Medical research
Medical researchMedical research
Medical research
Ms. Pooja Bhandare
 
Helsinki decleration
Helsinki declerationHelsinki decleration
Helsinki decleration
Radhika Chintamani
 
Research Methodology_UNIT_V_Declaration of Helsinki M. Pharm (IIIrd Sem.)
Research Methodology_UNIT_V_Declaration of Helsinki M. Pharm (IIIrd Sem.)Research Methodology_UNIT_V_Declaration of Helsinki M. Pharm (IIIrd Sem.)
Research Methodology_UNIT_V_Declaration of Helsinki M. Pharm (IIIrd Sem.)
Prachi Pandey
 
Biostat.
Biostat.Biostat.
Biostat.
Sachin kumar
 
Seminar on ethics committee, cultural concerns
Seminar on ethics committee, cultural concernsSeminar on ethics committee, cultural concerns
Seminar on ethics committee, cultural concerns
Priyanka Tambe
 
Declaration of-helsinki presantation
Declaration of-helsinki presantationDeclaration of-helsinki presantation
Declaration of-helsinki presantation
ManoharReddy183
 
Research methodology
Research methodologyResearch methodology
Research methodology
MUSTAFIZUR RAHMAN
 
Declaration of helsinki (Pharmacology SEM-III)
Declaration of helsinki (Pharmacology SEM-III)Declaration of helsinki (Pharmacology SEM-III)
Declaration of helsinki (Pharmacology SEM-III)
S.G.S.S. COLLEGE OF PHARMACY, MANUR
 
Criticisms of orthodox medical ethics, importance of
Criticisms of orthodox medical ethics, importance ofCriticisms of orthodox medical ethics, importance of
Criticisms of orthodox medical ethics, importance of
supriyawable1
 
Medical Ethics
Medical EthicsMedical Ethics
Medical Ethics
RuchiPal10
 

What's hot (20)

General research methodology mpharm
General research methodology  mpharmGeneral research methodology  mpharm
General research methodology mpharm
 
Vendor relationship...fatality.
Vendor relationship...fatality.Vendor relationship...fatality.
Vendor relationship...fatality.
 
Research Methodology General.ppt
Research  Methodology  General.pptResearch  Methodology  General.ppt
Research Methodology General.ppt
 
M. Pharm: Research Methodology and biostatics
M. Pharm: Research Methodology and biostatics M. Pharm: Research Methodology and biostatics
M. Pharm: Research Methodology and biostatics
 
Cross over design, Placebo and blinding techniques
Cross over design, Placebo and blinding techniques Cross over design, Placebo and blinding techniques
Cross over design, Placebo and blinding techniques
 
Research Methodology (M. Pharm, IIIrd Sem.)_UNIT_IV_CPCSEA Guidelines for Lab...
Research Methodology (M. Pharm, IIIrd Sem.)_UNIT_IV_CPCSEA Guidelines for Lab...Research Methodology (M. Pharm, IIIrd Sem.)_UNIT_IV_CPCSEA Guidelines for Lab...
Research Methodology (M. Pharm, IIIrd Sem.)_UNIT_IV_CPCSEA Guidelines for Lab...
 
Declaration of Helsinki
Declaration of HelsinkiDeclaration of Helsinki
Declaration of Helsinki
 
Declaration of helsinki powerpoint presentation
Declaration of helsinki powerpoint presentationDeclaration of helsinki powerpoint presentation
Declaration of helsinki powerpoint presentation
 
Choice of control group in clinical trials
Choice of control group in clinical trialsChoice of control group in clinical trials
Choice of control group in clinical trials
 
Medical research
Medical researchMedical research
Medical research
 
Helsinki decleration
Helsinki declerationHelsinki decleration
Helsinki decleration
 
Research Methodology_UNIT_V_Declaration of Helsinki M. Pharm (IIIrd Sem.)
Research Methodology_UNIT_V_Declaration of Helsinki M. Pharm (IIIrd Sem.)Research Methodology_UNIT_V_Declaration of Helsinki M. Pharm (IIIrd Sem.)
Research Methodology_UNIT_V_Declaration of Helsinki M. Pharm (IIIrd Sem.)
 
Biostat.
Biostat.Biostat.
Biostat.
 
Seminar on ethics committee, cultural concerns
Seminar on ethics committee, cultural concernsSeminar on ethics committee, cultural concerns
Seminar on ethics committee, cultural concerns
 
Declaration of-helsinki presantation
Declaration of-helsinki presantationDeclaration of-helsinki presantation
Declaration of-helsinki presantation
 
Research methodology
Research methodologyResearch methodology
Research methodology
 
Declaration of helsinki (Pharmacology SEM-III)
Declaration of helsinki (Pharmacology SEM-III)Declaration of helsinki (Pharmacology SEM-III)
Declaration of helsinki (Pharmacology SEM-III)
 
Criticisms of orthodox medical ethics, importance of
Criticisms of orthodox medical ethics, importance ofCriticisms of orthodox medical ethics, importance of
Criticisms of orthodox medical ethics, importance of
 
Medical Ethics
Medical EthicsMedical Ethics
Medical Ethics
 
Medical Ethics
Medical EthicsMedical Ethics
Medical Ethics
 

Similar to Research Methodology_UNIT_V_Declaration of Helsinki M. Pharm (IIIrd Sem.)

Clinical Aspect of Drug Discovery and Development PCO 413.pptx
Clinical Aspect of Drug Discovery and Development PCO 413.pptxClinical Aspect of Drug Discovery and Development PCO 413.pptx
Clinical Aspect of Drug Discovery and Development PCO 413.pptx
CoutyNess
 
Ethics in clinical research
Ethics in clinical researchEthics in clinical research
Ethics in clinical research
ARUNAYESUDAS
 
medicalresearch-research-methodologybiostatistics-231028034159-d884bb5e.pdf
medicalresearch-research-methodologybiostatistics-231028034159-d884bb5e.pdfmedicalresearch-research-methodologybiostatistics-231028034159-d884bb5e.pdf
medicalresearch-research-methodologybiostatistics-231028034159-d884bb5e.pdf
Prachi Pandey
 
Helsinki declaration
Helsinki declarationHelsinki declaration
Helsinki declaration
Simran Narang
 
Clinical trials
Clinical trialsClinical trials
Clinical trials
Ram Kumar Reddy
 
Clinical Trials Introduction
Clinical Trials IntroductionClinical Trials Introduction
Clinical Trials Introductionbiinoida
 
Importance of clinical trials in drug discovery
Importance of clinical trials in drug discoveryImportance of clinical trials in drug discovery
Importance of clinical trials in drug discovery
KarunaMane1
 
Terminology in clinical research
Terminology in clinical researchTerminology in clinical research
Terminology in clinical research
Sanjit Dhawale
 
Clinical Trial.pptx
Clinical Trial.pptxClinical Trial.pptx
Clinical Trial.pptx
CabdiZakiho
 
1670327194_887_Research_with_human_participation.pptx
1670327194_887_Research_with_human_participation.pptx1670327194_887_Research_with_human_participation.pptx
1670327194_887_Research_with_human_participation.pptx
VelmaPranayReddy
 
Presentation on Clinical Trial
Presentation on Clinical TrialPresentation on Clinical Trial
Presentation on Clinical Trial
Sandeepkarki13
 
Clinical reaserch 112070804001
Clinical reaserch 112070804001Clinical reaserch 112070804001
Clinical reaserch 112070804001
Patel Parth
 
CLINICAL DATA MANAGEMENT SAS CDM Online Learning
CLINICAL DATA MANAGEMENT SAS CDM Online LearningCLINICAL DATA MANAGEMENT SAS CDM Online Learning
CLINICAL DATA MANAGEMENT SAS CDM Online Learning
shanmukha rao dondapati
 
8-Clinical Trial Studies
8-Clinical Trial Studies8-Clinical Trial Studies
8-Clinical Trial Studies
ResearchGuru
 
Clinical reaserch 112070804001
Clinical reaserch 112070804001Clinical reaserch 112070804001
Clinical reaserch 112070804001Patel Parth
 
Thalidomide tragedy
Thalidomide tragedyThalidomide tragedy
Thalidomide tragedy
ClinosolIndia
 
Overview of Pharmacovigilance by Yash Dhikale | Zumbar Pote | Santosh Ghuge |...
Overview of Pharmacovigilance by Yash Dhikale | Zumbar Pote | Santosh Ghuge |...Overview of Pharmacovigilance by Yash Dhikale | Zumbar Pote | Santosh Ghuge |...
Overview of Pharmacovigilance by Yash Dhikale | Zumbar Pote | Santosh Ghuge |...
ijtsrd
 
Exploring Clinical Trials: How Research Can Help Us Better Detect, Diagnose, ...
Exploring Clinical Trials: How Research Can Help Us Better Detect, Diagnose, ...Exploring Clinical Trials: How Research Can Help Us Better Detect, Diagnose, ...
Exploring Clinical Trials: How Research Can Help Us Better Detect, Diagnose, ...
Ruchi Vahi
 

Similar to Research Methodology_UNIT_V_Declaration of Helsinki M. Pharm (IIIrd Sem.) (20)

Clinical Aspect of Drug Discovery and Development PCO 413.pptx
Clinical Aspect of Drug Discovery and Development PCO 413.pptxClinical Aspect of Drug Discovery and Development PCO 413.pptx
Clinical Aspect of Drug Discovery and Development PCO 413.pptx
 
Ethics in clinical research
Ethics in clinical researchEthics in clinical research
Ethics in clinical research
 
medicalresearch-research-methodologybiostatistics-231028034159-d884bb5e.pdf
medicalresearch-research-methodologybiostatistics-231028034159-d884bb5e.pdfmedicalresearch-research-methodologybiostatistics-231028034159-d884bb5e.pdf
medicalresearch-research-methodologybiostatistics-231028034159-d884bb5e.pdf
 
Helsinki declaration
Helsinki declarationHelsinki declaration
Helsinki declaration
 
Clinical trials
Clinical trialsClinical trials
Clinical trials
 
Clinical Trials Introduction
Clinical Trials IntroductionClinical Trials Introduction
Clinical Trials Introduction
 
Importance of clinical trials in drug discovery
Importance of clinical trials in drug discoveryImportance of clinical trials in drug discovery
Importance of clinical trials in drug discovery
 
Terminology in clinical research
Terminology in clinical researchTerminology in clinical research
Terminology in clinical research
 
Clinical Trial.pptx
Clinical Trial.pptxClinical Trial.pptx
Clinical Trial.pptx
 
1670327194_887_Research_with_human_participation.pptx
1670327194_887_Research_with_human_participation.pptx1670327194_887_Research_with_human_participation.pptx
1670327194_887_Research_with_human_participation.pptx
 
Presentation on Clinical Trial
Presentation on Clinical TrialPresentation on Clinical Trial
Presentation on Clinical Trial
 
Clinical reaserch 112070804001
Clinical reaserch 112070804001Clinical reaserch 112070804001
Clinical reaserch 112070804001
 
IMPLANT crswk
IMPLANT crswkIMPLANT crswk
IMPLANT crswk
 
CLINICAL DATA MANAGEMENT SAS CDM Online Learning
CLINICAL DATA MANAGEMENT SAS CDM Online LearningCLINICAL DATA MANAGEMENT SAS CDM Online Learning
CLINICAL DATA MANAGEMENT SAS CDM Online Learning
 
8-Clinical Trial Studies
8-Clinical Trial Studies8-Clinical Trial Studies
8-Clinical Trial Studies
 
Clinical Trials
Clinical TrialsClinical Trials
Clinical Trials
 
Clinical reaserch 112070804001
Clinical reaserch 112070804001Clinical reaserch 112070804001
Clinical reaserch 112070804001
 
Thalidomide tragedy
Thalidomide tragedyThalidomide tragedy
Thalidomide tragedy
 
Overview of Pharmacovigilance by Yash Dhikale | Zumbar Pote | Santosh Ghuge |...
Overview of Pharmacovigilance by Yash Dhikale | Zumbar Pote | Santosh Ghuge |...Overview of Pharmacovigilance by Yash Dhikale | Zumbar Pote | Santosh Ghuge |...
Overview of Pharmacovigilance by Yash Dhikale | Zumbar Pote | Santosh Ghuge |...
 
Exploring Clinical Trials: How Research Can Help Us Better Detect, Diagnose, ...
Exploring Clinical Trials: How Research Can Help Us Better Detect, Diagnose, ...Exploring Clinical Trials: How Research Can Help Us Better Detect, Diagnose, ...
Exploring Clinical Trials: How Research Can Help Us Better Detect, Diagnose, ...
 

More from RAHUL PAL

Software Used In Formulation Design Process- Minor Project [Bachelor].pdf
Software Used In Formulation Design Process- Minor Project [Bachelor].pdfSoftware Used In Formulation Design Process- Minor Project [Bachelor].pdf
Software Used In Formulation Design Process- Minor Project [Bachelor].pdf
RAHUL PAL
 
Major Project (B. Pharm) OPIUM POPPY PROJECT.pdf
Major Project (B. Pharm) OPIUM POPPY PROJECT.pdfMajor Project (B. Pharm) OPIUM POPPY PROJECT.pdf
Major Project (B. Pharm) OPIUM POPPY PROJECT.pdf
RAHUL PAL
 
Niosome Formulation And Evaluations .pdf
Niosome Formulation And Evaluations .pdfNiosome Formulation And Evaluations .pdf
Niosome Formulation And Evaluations .pdf
RAHUL PAL
 
Niosome An Non-Ionic Surfactant Vesicles.pptx
Niosome An Non-Ionic Surfactant Vesicles.pptxNiosome An Non-Ionic Surfactant Vesicles.pptx
Niosome An Non-Ionic Surfactant Vesicles.pptx
RAHUL PAL
 
𝐎𝐫𝐚𝐥 𝐏𝐚𝐩𝐞𝐫 𝐏𝐫𝐞𝐬𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧: 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞 (𝐈𝐑𝐓𝐄𝐂 𝟐.𝟎-𝟐𝟎𝟐𝟒); The Curre...
𝐎𝐫𝐚𝐥 𝐏𝐚𝐩𝐞𝐫 𝐏𝐫𝐞𝐬𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧: 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞 (𝐈𝐑𝐓𝐄𝐂 𝟐.𝟎-𝟐𝟎𝟐𝟒); The Curre...𝐎𝐫𝐚𝐥 𝐏𝐚𝐩𝐞𝐫 𝐏𝐫𝐞𝐬𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧: 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞 (𝐈𝐑𝐓𝐄𝐂 𝟐.𝟎-𝟐𝟎𝟐𝟒); The Curre...
𝐎𝐫𝐚𝐥 𝐏𝐚𝐩𝐞𝐫 𝐏𝐫𝐞𝐬𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧: 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞 (𝐈𝐑𝐓𝐄𝐂 𝟐.𝟎-𝟐𝟎𝟐𝟒); The Curre...
RAHUL PAL
 
Thakur35352024JPRI111654.pdf
Thakur35352024JPRI111654.pdfThakur35352024JPRI111654.pdf
Thakur35352024JPRI111654.pdf
RAHUL PAL
 
THE CURRENT STATUS IN MUCOSAL DRUG DELIVERY SYSTEM (MDDS) AND FUTURE PROSPECT...
THE CURRENT STATUS IN MUCOSAL DRUG DELIVERY SYSTEM (MDDS) AND FUTURE PROSPECT...THE CURRENT STATUS IN MUCOSAL DRUG DELIVERY SYSTEM (MDDS) AND FUTURE PROSPECT...
THE CURRENT STATUS IN MUCOSAL DRUG DELIVERY SYSTEM (MDDS) AND FUTURE PROSPECT...
RAHUL PAL
 
Design of Experiments (DoE) manipulation in the formulation and optimization ...
Design of Experiments (DoE) manipulation in the formulation and optimization ...Design of Experiments (DoE) manipulation in the formulation and optimization ...
Design of Experiments (DoE) manipulation in the formulation and optimization ...
RAHUL PAL
 
The Utilization of 32 Full Factorial Design (FFD) for Optimization of Linco...
The Utilization of 32 Full Factorial  Design (FFD) for Optimization of  Linco...The Utilization of 32 Full Factorial  Design (FFD) for Optimization of  Linco...
The Utilization of 32 Full Factorial Design (FFD) for Optimization of Linco...
RAHUL PAL
 
Determination of Partition coefficient of Known and Unknown drug.pdf
Determination of Partition coefficient of Known and Unknown drug.pdfDetermination of Partition coefficient of Known and Unknown drug.pdf
Determination of Partition coefficient of Known and Unknown drug.pdf
RAHUL PAL
 
Pharmaceutical Suspension.ppt
Pharmaceutical Suspension.pptPharmaceutical Suspension.ppt
Pharmaceutical Suspension.ppt
RAHUL PAL
 
PHARMACEUTICAL SUPPOSITORIES & PESSARIES.ppt
PHARMACEUTICAL SUPPOSITORIES & PESSARIES.pptPHARMACEUTICAL SUPPOSITORIES & PESSARIES.ppt
PHARMACEUTICAL SUPPOSITORIES & PESSARIES.ppt
RAHUL PAL
 
Partition Coefficient Determination (Pharmaceutics Practical).pptx
Partition Coefficient Determination (Pharmaceutics Practical).pptxPartition Coefficient Determination (Pharmaceutics Practical).pptx
Partition Coefficient Determination (Pharmaceutics Practical).pptx
RAHUL PAL
 
The Utilization of Response Surface Methodology (RSM) In the Optimization of ...
The Utilization of Response Surface Methodology (RSM) In the Optimization of ...The Utilization of Response Surface Methodology (RSM) In the Optimization of ...
The Utilization of Response Surface Methodology (RSM) In the Optimization of ...
RAHUL PAL
 
Research Article Published: "Optimization and formulation of dox loaded lipos...
Research Article Published: "Optimization and formulation of dox loaded lipos...Research Article Published: "Optimization and formulation of dox loaded lipos...
Research Article Published: "Optimization and formulation of dox loaded lipos...
RAHUL PAL
 
Nucleic Acid Based Therapeutics Delivery.pdf
Nucleic Acid Based Therapeutics Delivery.pdfNucleic Acid Based Therapeutics Delivery.pdf
Nucleic Acid Based Therapeutics Delivery.pdf
RAHUL PAL
 
Introduction to Pharmacy.pptx
Introduction to Pharmacy.pptxIntroduction to Pharmacy.pptx
Introduction to Pharmacy.pptx
RAHUL PAL
 
Gas Chromatography in Analytical Analysis.pptx
Gas Chromatography in Analytical Analysis.pptxGas Chromatography in Analytical Analysis.pptx
Gas Chromatography in Analytical Analysis.pptx
RAHUL PAL
 
Monoclonal Antibody-Preparation & Application - MPH201T.pptx
Monoclonal Antibody-Preparation & Application - MPH201T.pptxMonoclonal Antibody-Preparation & Application - MPH201T.pptx
Monoclonal Antibody-Preparation & Application - MPH201T.pptx
RAHUL PAL
 
Introduction to Pharmacy & Pharmaceutics.pptx
Introduction to Pharmacy & Pharmaceutics.pptxIntroduction to Pharmacy & Pharmaceutics.pptx
Introduction to Pharmacy & Pharmaceutics.pptx
RAHUL PAL
 

More from RAHUL PAL (20)

Software Used In Formulation Design Process- Minor Project [Bachelor].pdf
Software Used In Formulation Design Process- Minor Project [Bachelor].pdfSoftware Used In Formulation Design Process- Minor Project [Bachelor].pdf
Software Used In Formulation Design Process- Minor Project [Bachelor].pdf
 
Major Project (B. Pharm) OPIUM POPPY PROJECT.pdf
Major Project (B. Pharm) OPIUM POPPY PROJECT.pdfMajor Project (B. Pharm) OPIUM POPPY PROJECT.pdf
Major Project (B. Pharm) OPIUM POPPY PROJECT.pdf
 
Niosome Formulation And Evaluations .pdf
Niosome Formulation And Evaluations .pdfNiosome Formulation And Evaluations .pdf
Niosome Formulation And Evaluations .pdf
 
Niosome An Non-Ionic Surfactant Vesicles.pptx
Niosome An Non-Ionic Surfactant Vesicles.pptxNiosome An Non-Ionic Surfactant Vesicles.pptx
Niosome An Non-Ionic Surfactant Vesicles.pptx
 
𝐎𝐫𝐚𝐥 𝐏𝐚𝐩𝐞𝐫 𝐏𝐫𝐞𝐬𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧: 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞 (𝐈𝐑𝐓𝐄𝐂 𝟐.𝟎-𝟐𝟎𝟐𝟒); The Curre...
𝐎𝐫𝐚𝐥 𝐏𝐚𝐩𝐞𝐫 𝐏𝐫𝐞𝐬𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧: 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞 (𝐈𝐑𝐓𝐄𝐂 𝟐.𝟎-𝟐𝟎𝟐𝟒); The Curre...𝐎𝐫𝐚𝐥 𝐏𝐚𝐩𝐞𝐫 𝐏𝐫𝐞𝐬𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧: 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞 (𝐈𝐑𝐓𝐄𝐂 𝟐.𝟎-𝟐𝟎𝟐𝟒); The Curre...
𝐎𝐫𝐚𝐥 𝐏𝐚𝐩𝐞𝐫 𝐏𝐫𝐞𝐬𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧: 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞 (𝐈𝐑𝐓𝐄𝐂 𝟐.𝟎-𝟐𝟎𝟐𝟒); The Curre...
 
Thakur35352024JPRI111654.pdf
Thakur35352024JPRI111654.pdfThakur35352024JPRI111654.pdf
Thakur35352024JPRI111654.pdf
 
THE CURRENT STATUS IN MUCOSAL DRUG DELIVERY SYSTEM (MDDS) AND FUTURE PROSPECT...
THE CURRENT STATUS IN MUCOSAL DRUG DELIVERY SYSTEM (MDDS) AND FUTURE PROSPECT...THE CURRENT STATUS IN MUCOSAL DRUG DELIVERY SYSTEM (MDDS) AND FUTURE PROSPECT...
THE CURRENT STATUS IN MUCOSAL DRUG DELIVERY SYSTEM (MDDS) AND FUTURE PROSPECT...
 
Design of Experiments (DoE) manipulation in the formulation and optimization ...
Design of Experiments (DoE) manipulation in the formulation and optimization ...Design of Experiments (DoE) manipulation in the formulation and optimization ...
Design of Experiments (DoE) manipulation in the formulation and optimization ...
 
The Utilization of 32 Full Factorial Design (FFD) for Optimization of Linco...
The Utilization of 32 Full Factorial  Design (FFD) for Optimization of  Linco...The Utilization of 32 Full Factorial  Design (FFD) for Optimization of  Linco...
The Utilization of 32 Full Factorial Design (FFD) for Optimization of Linco...
 
Determination of Partition coefficient of Known and Unknown drug.pdf
Determination of Partition coefficient of Known and Unknown drug.pdfDetermination of Partition coefficient of Known and Unknown drug.pdf
Determination of Partition coefficient of Known and Unknown drug.pdf
 
Pharmaceutical Suspension.ppt
Pharmaceutical Suspension.pptPharmaceutical Suspension.ppt
Pharmaceutical Suspension.ppt
 
PHARMACEUTICAL SUPPOSITORIES & PESSARIES.ppt
PHARMACEUTICAL SUPPOSITORIES & PESSARIES.pptPHARMACEUTICAL SUPPOSITORIES & PESSARIES.ppt
PHARMACEUTICAL SUPPOSITORIES & PESSARIES.ppt
 
Partition Coefficient Determination (Pharmaceutics Practical).pptx
Partition Coefficient Determination (Pharmaceutics Practical).pptxPartition Coefficient Determination (Pharmaceutics Practical).pptx
Partition Coefficient Determination (Pharmaceutics Practical).pptx
 
The Utilization of Response Surface Methodology (RSM) In the Optimization of ...
The Utilization of Response Surface Methodology (RSM) In the Optimization of ...The Utilization of Response Surface Methodology (RSM) In the Optimization of ...
The Utilization of Response Surface Methodology (RSM) In the Optimization of ...
 
Research Article Published: "Optimization and formulation of dox loaded lipos...
Research Article Published: "Optimization and formulation of dox loaded lipos...Research Article Published: "Optimization and formulation of dox loaded lipos...
Research Article Published: "Optimization and formulation of dox loaded lipos...
 
Nucleic Acid Based Therapeutics Delivery.pdf
Nucleic Acid Based Therapeutics Delivery.pdfNucleic Acid Based Therapeutics Delivery.pdf
Nucleic Acid Based Therapeutics Delivery.pdf
 
Introduction to Pharmacy.pptx
Introduction to Pharmacy.pptxIntroduction to Pharmacy.pptx
Introduction to Pharmacy.pptx
 
Gas Chromatography in Analytical Analysis.pptx
Gas Chromatography in Analytical Analysis.pptxGas Chromatography in Analytical Analysis.pptx
Gas Chromatography in Analytical Analysis.pptx
 
Monoclonal Antibody-Preparation & Application - MPH201T.pptx
Monoclonal Antibody-Preparation & Application - MPH201T.pptxMonoclonal Antibody-Preparation & Application - MPH201T.pptx
Monoclonal Antibody-Preparation & Application - MPH201T.pptx
 
Introduction to Pharmacy & Pharmaceutics.pptx
Introduction to Pharmacy & Pharmaceutics.pptxIntroduction to Pharmacy & Pharmaceutics.pptx
Introduction to Pharmacy & Pharmaceutics.pptx
 

Recently uploaded

How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...
Jisc
 
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
Levi Shapiro
 
2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...
Sandy Millin
 
How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17
Celine George
 
Chapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptxChapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptx
Mohd Adib Abd Muin, Senior Lecturer at Universiti Utara Malaysia
 
Unit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdfUnit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdf
Thiyagu K
 
Embracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic ImperativeEmbracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic Imperative
Peter Windle
 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
siemaillard
 
"Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe..."Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe...
SACHIN R KONDAGURI
 
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
EugeneSaldivar
 
CACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdfCACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdf
camakaiclarkmusic
 
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCECLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
BhavyaRajput3
 
The Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdfThe Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdf
kaushalkr1407
 
The basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptxThe basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptx
heathfieldcps1
 
Francesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptxFrancesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptx
EduSkills OECD
 
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXXPhrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
MIRIAMSALINAS13
 
1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx
JosvitaDsouza2
 
The approach at University of Liverpool.pptx
The approach at University of Liverpool.pptxThe approach at University of Liverpool.pptx
The approach at University of Liverpool.pptx
Jisc
 
Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345
beazzy04
 
Honest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptxHonest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptx
timhan337
 

Recently uploaded (20)

How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...How libraries can support authors with open access requirements for UKRI fund...
How libraries can support authors with open access requirements for UKRI fund...
 
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
 
2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...2024.06.01 Introducing a competency framework for languag learning materials ...
2024.06.01 Introducing a competency framework for languag learning materials ...
 
How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17How to Make a Field invisible in Odoo 17
How to Make a Field invisible in Odoo 17
 
Chapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptxChapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptx
 
Unit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdfUnit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdf
 
Embracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic ImperativeEmbracing GenAI - A Strategic Imperative
Embracing GenAI - A Strategic Imperative
 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
 
"Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe..."Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe...
 
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
 
CACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdfCACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdf
 
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCECLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
CLASS 11 CBSE B.St Project AIDS TO TRADE - INSURANCE
 
The Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdfThe Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdf
 
The basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptxThe basics of sentences session 5pptx.pptx
The basics of sentences session 5pptx.pptx
 
Francesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptxFrancesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptx
 
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXXPhrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
Phrasal Verbs.XXXXXXXXXXXXXXXXXXXXXXXXXX
 
1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx
 
The approach at University of Liverpool.pptx
The approach at University of Liverpool.pptxThe approach at University of Liverpool.pptx
The approach at University of Liverpool.pptx
 
Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345
 
Honest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptxHonest Reviews of Tim Han LMA Course Program.pptx
Honest Reviews of Tim Han LMA Course Program.pptx
 

Research Methodology_UNIT_V_Declaration of Helsinki M. Pharm (IIIrd Sem.)

  • 1. DECLARATION OF HELSINKI (UNIT V) SUBMITTED BY: PRACHI PANDEY, RAHUL PAL M. PHARM (PHARMACEUTICS), IIIRD SEM, RESEARCH METHEDOLOGY AND BIOSTATISTICS DEPARTMENT OF PHARMACEUTICS, NIMS INSTITUTE OF PHARMACY, NIMS UNIVERSITY, JAIPUR, RAJASTHAN, 303121, INDIA.
  • 2. DECLARATION OF HELSINKI  It is a set of ethical principles basically for clinical trails followed by medical researchers and given by World Medical Association.  As physician’s (investigator) duty in research is to protect the life, health, privacy and dignity of human participant oversight by Institutional Review Board (IRB); Research Ethical Committee (REC) or Ethical Review Board (ERB).  Declaration of Helsinki was followed by Nuremberg code (because of nazii experiments) and Thalidomide disaster {which was a pharmacovigilance failure; where pregnant women’s morning sickness was tried to overcome by drug that lead to delivery of babies without limbs (phocomelia)}.  9 Amendments in 1975, 1983, 1989, 1996, 2000, 2002, 2004, 2008, 2013.  Regarded as cornerstone documents for human ethics.
  • 3. HISTORY  Adopted in June 1964.  Amendments- 1975, 1983, 1989, 1996,2000,2002,2004,2008,2013  First significant effort by medical community to regulate research.  Prior to 1947 Nuremberg code only specific countries has National policies. (Germany Russia)  Forms basis of most subsequent documents  1947 declaration of the Nuremberg Code1948 declaration of Geneva  Declaration of Geneva (1948) - the WMA binds the physician with the words. "The health of my patient will be my first consideration".
  • 4. GENERAL STATEMENT  Purpose- directed towards the increase of knowledge about the human condition in relation to its social and natural environment.  Research is for the betterment of all.  Conducted- dignity and well being. professional fair treatment and transparency no greater risk.  Evaluation- all stages of proposal (research design, experimentation, deceleration of results, use of results) benefits and dangers. GOAL NEW KNOWLEDDE
  • 5. PRINCIPLE  First Principle – Objective of study is to outweigh risk. If risk is more either modify or stop the study along with every thing must be monitored, assessed, documented with minimum risk.  Second Principle – If vulnerable groups (pregnancy, sensitive, children, elderly, psychological issues) are involved then increase chance additional harm protection must be provided along with consent even with minors  Third Principle - Before human study, scientific literature, lab and animal experiments is must to be read; statements like regarding funding, sponsors, institutional afflation's, potential conflict of interest must be submitted; research involving humans must confirm to generally accepted scientific principles and through knowledge of scientific literature and methods; literature review and animal experiments must be prior to human research.
  • 6. PRINCIPLE  Four Principle (Research Ethical Committee) – Before study, design to conduct the experiment must be given to the National and International Ethical norms. Research submission about the final report with study finding and conclusion in end of the study; research protocol must be reviewed by an independent committee and conduct by medically/ scientifically qualified individuals; main aim is the participant health, introduction to ethical committee, responsibility to check again and again, increase revolutionary decision. If not done they have a reason to stop/ declare invalid.  Five Principle (Privacy and Confidentiality) – Human subject and information must be private. Dignity, privacy, confidentiality, participant’s physical/ mental integrity and life of participants should be protected.
  • 7. PRINCIPLE  Six Principle (Informed Consent) – It is a written consent about the experiment that has to be conducted by the volunteer independently after knowing about research and It must have aim, method, conflict of interest, function, general outcome of study, voluntary , legally authorative represerntative.  Seven Principle (Results) – Investigators are obliged to preserve the accuracy of results, negative and positive results should be publically available.  Eight Principle (Use of Placebo) – Intervention should be given (+) impact. CARE- avoid abuse of this option.  Nine Priciple (Post trail Provision) – Explain human subjects and provide help.  Ten Principle (Unproven intervention in clinical practice) – Evaluate the efficacy and safety; new information will be recorded and publically available.
  • 8. ADDITIONAL PRINCIPLE  The physician may combine medical research with medical care, only to the extent that the research is justified by its potential prophylactic, diagnostic or therapeutic value.  When medical research is combined with medical care, additional standards apply to protect the patients who are research subjects.  The benefits, risks, burdens and effectiveness of a new method should be tested against those of the best current prophylactic, diagnostic, and therapeutic methods. This does not exclude the use of placebo, or no treatment, in studies where no proven prophylactic, diagnostic or theraptic method exists.  At the conclusion of the study, every patient entered into the study should be assured of access to the best proven prophylactic, diagnostic and therapeutic methods identified by the study.
  • 9. ADDITIONAL PRINCIPLE  The physician should fully inform the patient which aspects of the care are related to the research. The refusal of a patient to participate in a study must never interfere with the patient-physician relationship.  In the treatment of a patient, where proven prophylactic, diagnostic and therapeutic methods do not exist or have been ineffective, the physician, with informed consent from the patient, must be free to use unproven or new prophylactic, diagnostic and therapeutic measures, if in the physician's judgment it offers hope of saving life, reestablishing health or alleviating suffering. Where possible, these measures should be made the object of research, designed to evaluate their safety and efficacy. In all cases, new information should be recorded and, where appropriate, published. The other relevant guidelines of this Declaration should be followed.